Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing by Liang, Winnie S. et al.
Genome-Wide Characterization of Pancreatic
Adenocarcinoma Patients Using Next Generation
Sequencing
Winnie S. Liang1., David W. Craig1., John Carpten1., Mitesh J. Borad2., Michael J. Demeure1,3,
Glen J. Weiss1,3, Tyler Izatt1, Shripad Sinari1, Alexis Christoforides1, Jessica Aldrich1, Ahmet Kurdoglu1,
Michael Barrett1, Lori Phillips1, Hollie Benson1, Waibhav Tembe1, Esteban Braggio2, Jeffrey A. Kiefer1,
Christophe Legendre1, Richard Posner1, Galen H. Hostetter1, Angela Baker1, Jan B. Egan1,2,
Haiyong Han1, Douglas Lake4, Edward C. Stites1, Ramesh K. Ramanathan1,3, Rafael Fonseca2,
A. Keith Stewart2, Daniel Von Hoff1,2,3*
1 Translational Genomics Research Institute (TGen), Phoenix, Arizona, United States of America, 2Mayo Clinic, Scottsdale, Arizona, United States of America, 3 Virginia G.
Piper Cancer Center Clinical Trials, Scottsdale Healthcare, Scottsdale, Arizona, United States of America, 4Arizona State University, Tempe, Arizona, United States of
America
Abstract
Pancreatic adenocarcinoma (PAC) is among the most lethal malignancies. While research has implicated multiple genes in
disease pathogenesis, identification of therapeutic leads has been difficult and the majority of currently available therapies
provide only marginal benefit. To address this issue, our goal was to genomically characterize individual PAC patients to
understand the range of aberrations that are occurring in each tumor. Because our understanding of PAC tumorigenesis is
limited, evaluation of separate cases may reveal aberrations, that are less common but may provide relevant information on
the disease, or that may represent viable therapeutic targets for the patient. We used next generation sequencing to assess
global somatic events across 3 PAC patients to characterize each patient and to identify potential targets. This study is the
first to report whole genome sequencing (WGS) findings in paired tumor/normal samples collected from 3 separate PAC
patients. We generated on average 132 billion mappable bases across all patients using WGS, and identified 142 somatic
coding events including point mutations, insertion/deletions, and chromosomal copy number variants. We did not identify
any significant somatic translocation events. We also performed RNA sequencing on 2 of these patients’ tumors for which
tumor RNA was available to evaluate expression changes that may be associated with somatic events, and generated over
100 million mapped reads for each patient. We further performed pathway analysis of all sequencing data to identify
processes that may be the most heavily impacted from somatic and expression alterations. As expected, the KRAS signaling
pathway was the most heavily impacted pathway (P,0.05), along with tumor-stroma interactions and tumor suppressive
pathways. While sequencing of more patients is needed, the high resolution genomic and transcriptomic information we
have acquired here provides valuable information on the molecular composition of PAC and helps to establish a foundation
for improved therapeutic selection.
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Introduction
Pancreatic cancer is a malignant carcinoma that is currently the
fourth leading cause of cancer-related deaths in the United States
[1]. In 2011, an estimated 44,030 new patients were diagnosed,
and the one- and five-year survival rates were approximately 26%
and 6%, respectively [1]. Current standard treatment options for
patients include surgical removal of the tumor, radiation therapy,
chemotherapy, and targeted/biologic therapy. However, due to
late diagnoses and the associated low survival rate, improved
treatments are needed.
Significant effort by a number of groups has led to the
identification of genomic alterations in pancreatic cancer. Heavily
implicated genes include KRAS (v-Ki-ras2 Kirsten rat sarcoma
viral oncogene homolog ) [2,3], TP53 (tumor protein p53) [4,5],
SMAD4/DPC4 (SMAD family member 4/deletion target in
pancreatic carcinoma 4 homolog) [6,7], CDKN2A (cyclin-depen-
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dent kinase inhibitor 2A; p16) [8,9,10], and BRCA2 (breast cancer
2, early onset) [11,12]. However, FDA approved therapies that
exploit these genomic alterations in pancreatic cancer are
currently not available. As a result, standard agent therapy for
advanced stage and metastatic pancreatic adenocarcinoma (PAC)
patients commonly target tumor DNA replication, cell division,
and proliferation, or specific receptors that help to mediate
signaling cascades. While PAC patients commonly have mutations
in the previously mentioned genes, low survival rates for PAC
patients are associated with difficulty in identifying effective
treatments beyond standard therapies. Such difficulty associated
with finding effective treatments demonstrates that our under-
standing of pancreatic cancer remains limited. In order to address
these challenges, one strategy is to first individually characterize
patients to fully understand the range of alterations in separate
tumors. In doing so, we acquire valuable information on each
patient’s disease, as well as PAC as a whole, and are also able to
identify druggable targets that may provide additional therapeutic
options on a patient-specific basis. This approach is particularly
relevant because although certain mutations are common across
patients, each patient’s tumor demonstrates divergent aberrations.
As we acquire more tumor DNA and RNA sequence information
from actual patients, we will also be able to delineate the key
biological processes that are central to PAC and develop improved
therapies for patients.
To carry out unbiased whole genome analyses in actual
patients, we performed whole genome sequencing (WGS) of
tumor biopsy DNA and matched normal DNA from blood from
three separate PAC patients to identify somatic events in each
patient’s tumor. Our primary aim is to separately characterize
each of these patients to evaluate the molecular background of
each tumor. To understand the possible implications of identified
genomic events and to evaluate transcriptional alterations in the
tumor, we also performed RNA sequencing (RNAseq) for 2 of the
patients for which RNA was available. Lastly, for patients 1 and 2,
we performed comparative genomic hybridization (CGH) analyses
to validate copy number changes identified through sequencing.
The use of next generation sequencing (NGS) and the combined
analysis of separate sets of data help to create a detailed picture of
the disease in each patient and contribute to our understanding of
the disease. We present here very detailed genomic characteriza-
tions of three separate PAC patients.
Materials and Methods
Detailed supplementary methods are described under Support-
ing Information (Methods S1). A summary of methods is presented
here.
Ethics statement
All patients were treated on protocols approved by the Mayo
Clinic Institutional Review Board (MCIRB) and the Western
Institutional Review Board (WIRB). This study was conducted in
accordance with the 1996 Declaration of Helsinki. Written
informed consent was obtained from all patients.
Eligibility Criteria
For this study, patients had to be$18 years of age and provided
signed informed consent. These patients included those with a
pathologic or clinical diagnosis of a pancreatic malignant
neoplasm, or who were undergoing a medically indicated
procedure to obtain tissue or to resect their pancreatic tumor.
Other eligibility criteria included: Karnofsky performance status
(PS) $80%, life expectancy .3 months, baseline laboratory data
indicating acceptable bone marrow reserve, liver, and renal
function. Patients were allowed to participate on another clinical
trial involving treatment prior to or during participation on this
study. Main exclusion criteria included: symptomatic central
nervous system (CNS) metastasis, untreated CNS metastases,
known active infections requiring intravenous antimicrobial
therapy, known HIV, HBV or HCV infection requiring antiviral
therapy, pregnant or breast feeding women, or inaccessible tumor
for biopsy.
Sample assessment
Tumor samples were obtained under institutional review
protocols and were preserved as fresh frozen. Normal DNA was
obtained from peripheral blood mononuclear cells. Percent tumor
cellularity of patient 1’s biopsy (tumor content) was assessed as
60% tumor, patient 2 50% tumor, and patient 3 40–50% tumor.
Direct visualization of samples collected from all three patients was
obtained to estimate tumor content and extent of tissue
heterogeneity by a board certified pathologist (GH).
Genomic DNA isolation
Tissue was disrupted and homogenized in Buffer RLT plus
(Qiagen AllPrep DNA/RNA Mini Kit), using the Bullet
BlenderTM, Next Advance, and transferred to a microcentrifuge
tube containing Buffer RLT plus and 1.6 mm stainless steel beads
(patient 1), or 0.9 mm–2.0 mm RNase free stainless steel beads
(patients 2 and 3). Blood leukocytes (buffy coat) were isolated from
whole blood by centrifugation at room temperature and
resuspended in Buffer RLT plus. All samples were homogenized,
centrifuged at full speed, and lysates were transferred to the
Qiagen AllPrep DNA spin column. Genomic DNA was purified
following the manufacturer’s protocol. DNA was quantified using
the Nanodrop spectrophotometer and quality was accessed from
260/280 and 260/230 absorbance ratios.
RNA Isolation
Tissue was disrupted and homogenized in Buffer RLT plus
using the Bullet Blender, and transferred to a microcentrifuge tube
containing Buffer RLT plus and 0.9 mm–2.0 mm RNAse free
stainless steel beads. The tissue was homogenized in the Bullet
Blender, and centrifuged at full speed. The supernatant was
transferred to the QiagenAllPrep DNA spin column. 70% ethanol
was added to the flow-through and the mixture was applied to an
RNeasy spin column. Total RNA purification was conducted as
directed by the AllPrep DNA/RNA Mini Handbook. FirstChoice
normal human pancreatic RNA was purchased from Ambion
(catalog#AM7954) and used as the RNAseq control. RNA was
quantified using the Nanodrop spectrophotometer and quality was
assessed using the Agilent Bioanalyzer.
Whole genome library preparation
3 mg of genomic DNA from each sample was fragmented to a
target size of 300–350 base pairs (bp). Overhangs in the
fragmented samples were repaired and adenine bases were ligated
on. Diluted paired end Illumina adapters were then ligated onto
the A-tailed products. Following ligation, samples were run on a
3% TAE gel to separate products. Ligation products at 300 bp
and 350 bp were selected for each sample, isolated from gel
punches, and purified. 26Phusion High-Fidelity PCR Master Mix
(Finnzymes; catalog#F-531L) was used to perform PCR to enrich
for these products. Enriched PCR products were run on a 2%
TAE gel and extracted. Products were quantified using Agilent’s
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High Sensitivity DNA chip (catalog#5067-4626) on the Agilent
2100 Bioanalyzer (catalog#G2939AA).
Whole transcriptome library preparation
All RNA samples were analyzed on the Agilent Bioanalyzer
RNA 6000 Nano Chip to validate RNA integrity (RIN$7.0).
10 ng of total RNA was used to generate whole transcriptome
libraries for RNA sequencing. Using the Nugen Ovation RNA-
Seq System (cat#7100-08), total RNA was used to generate
double stranded cDNA, which was amplified using Nugen’s SPIA
linear amplification process. Amplified cDNA was input into
Illumina’s TruSeq DNA Sample Preparation Kit – Set A
(cat#FC-121-1001) for library preparation. In summary, 1 mg of
amplified cDNA was fragmented to a target insert size of 300 bp
and end repaired. Samples were then adenylated and indexed
paired end adapters were ligated. Ligation products were run on a
2% TAE gel and size selected at 400 bp. Ligation products were
isolated from gel punches and purified. Cleaned ligation products
were input into PCR to enrich for libraries. PCR products were
cleaned and quantified using the Agilent Bioanalyzer.
PE next generation sequencing
Tumor and normal libraries were prepared for paired end
sequencing. Clusters were generated using Illumina’s cBot and
HiSeq Paired End Cluster Generation Kits (catalog#PE-401-
1001) and sequenced on Illumina’s HiSeq 2000 using Illumina’-
sHiSeq Sequencing Kit (catalog#FC-401-1001).
Array CGH (aCGH) for patient 1
Samples were run with the SurePrint G3 Human aCGH
Microarray 1 M (Agilent Technologies, Palo Alto, CA). The
digestion, labeling, and hybridization steps were performed as
previously described with minor modifications [13]. Briefly, 1.2 ug
of tumor and reference DNA were independently digested with
Bovine DNase I (Ambion, Austin, TX) for 12 minutes at room
temperature. DNA samples from a pool of nine human, female,
lymphoblastoid cell lines from the Coriell repository (NA18517,
NA19240, NA18555, NA18537, NA18980, NA18972, NA12878,
NA12156, and NA15510) were used as the normal reference in the
hybridization experiments. Tumor samples were labeled with Cy5
dye, and the normal reference was labeled with Cy3 dye. Labeled
reactions were cleaned up and hybridized at 65uC for 40 hours.
Microarrays were scanned and features were extracted with
Feature Extraction software (Agilent Technologies). Log2 ratio
data was analyzed using Genomic Workbench software version
5.0.14 (Agilent Technologies).
Flow cytometry CGH for patient 2
DNA content based flow assays were used to identify and purify
proliferating 2N (G1) populations, 4N(G2/M), and aneuploid
populations from the biopsy. The biopsy was minced in the
presence of NST buffer and DAPI according to published
protocols [14,15]. Nuclei were disaggregated immediately before
analysis with a 25-gauge needle and then filtered through a 40-mm
mesh filter and analyzed using an Influx cytometer (Becton-
Dickinson Cytopeia, San Jose CA), with ultraviolet excitation and
DAPI emission collected at .450 nm. DNA content and cell cycle
were analyzed using the software program WinCycle (Phoenix
Flow Systems, San Diego, CA). DNAs were extracted using
Qiagen micro kits (Qiagen Valencia, CA). For hybridization,
100 ng of genomic DNA from each sample and of pooled
commercial 46XX reference (Promega) were amplified using the
GenomiPhi amplification kit (G.E. Healthcare, Piscataway, NJ).
1 ug of amplified sample and 1 ug of amplified reference template
were digested with DNaseI and labeled with Cy-5 dUTP and Cy-3
dUTP respectively, using a BioPrime labeling kit (Invitrogen,
Carlsbad, CA). All labeling reactions were assessed using a
Nanodrop assay (Nanodrop, Wilmington, DE) prior to mixing and
hybridization to a CGH array (Agilent Technologies, Santa Clara,
CA).
Sequencing data analysis
Raw sequence data in the form of .bcl files were generated by
the Illumina HiSeq 2000. These data were converted to .qseq files,
which were used to generate .fastq files. Fastq files were validated
to evaluate the distribution of quality scores and to ensure that
quality scores do not drastically drop over each read. Validated
fastq files were aligned to the human reference genome (build 36)
using the Burrows-Wheeler Alignment (BWA) tool. Following
alignment,.sai files were used to create .sam (sequence alignment
map) files [16], which were input into SAMtools to create binary
sequence (.bam) files. PCR duplicates were flagged for removal
using Picard. Indels were realigned and base quality scores were
recalibrated using GATK (Genome Analysis Toolkit) [17].
Mutation analysis was performed to identify SNPs, indels, and
CNVs. Circos plots were generated for each patient to summarize
results from all variant analyses (Figures 1, 2, and 3). NCBI
(National Center for Biotechnology Information) SRA (Sequence
Read Archive) accession numbers for each patient are as follows—
patient 1 DNA: SRS334038, SRS334039; patient 2 DNA:
SRS334040, SRS334041; patient 2 RNA: SRS348787; patient 3
DNA: SRS334042, SRS334045; patient 3 RNA: SRS348788;
pancreas RNA control: SRS334047).
SNP (single nucleotide polymorphism) calling was performed
using SolSNP (http://sourceforge.net/projects/solsnp/) and Mu-
tation Walker, a tool developed in house and that incorporates
variant discovery tools from GATK. SNPs that were called using
both tools were compiled and visually examined for false positives
to create a final filtered list of true SNVs (single nucleotide
variants). Indel (insertion/deletion) calling was performed using
GATK and a somatic indel detection tool developed in house.
SIFT (Sorting Intolerant From Tolerant) or PolyPhen-2 (Poly-
morphism Phenotyping v2) was used to determine the effect of
coding SNV’s and indels on protein function. Copy number
analysis was completed by determining the log2 difference of the
normalized physical coverage (or clonal coverage) for both
germline and tumor samples separately across a sliding 2 kb
window of the mean. CREST (Clipping Reveals Structure) was
used on WGS data to identify structural variations [18].
RNAseq data was aligned against human reference genome
(build 36) with TopHat 1.2; RNAseq reads were only aligned
against the autosomes and sex chromosomes. Mitochondrial DNA
and annotations were removed from the genome and annotation
references prior to alignment. Cuffdiff was used to identify
differentially expressed genes and isoforms. Differential analysis
was performed on FPKM (Fragments Per Kilobase of transcript
per Million fragments mapped) expression values calculated for
gene and isoform. P-values were corrected for multiple testing
using the Benjamini and Hochberg method. ChimeraScan [19]
was used for fusion transcript detection.
Pathway analysis. Integrative analysis of whole genome and
transcriptomic data was performed using the Functional Ontology
Enrichment Tool in MetaCore from GeneGo, Inc. (v6.8;
Thomson Reuters Business, Philadelphia, PA). Pathway analysis
specific to pancreatic cancer was performed using the MetaMiner
(Oncology) Pancreatic Cancer Disease Module add-on. P-values
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Our study was performed on a set of fresh pancreatic tumor
specimens and whole blood samples from three patients diagnosed
with PAC. Clinical information is listed in Table 1. For each
patient, we sequenced both tumor DNA, as well as germline DNA
isolated from whole blood in order to identify somatic changes in
the tumors. Read alignment was performed with BWA using build
36 of the human reference genome. WGS metrics and summary
statistics for each of the three patients are shown in Table 2. Using
sequencing by synthesis technology and 100 bp paired end
chemistry, we generated nearly 8 billion total reads from WGS
for average mapped coverages ranging from 316 to 546. SNP
calling was performed using two separate callers to reduce the false
negative rate. To evaluate the overall quality of variant data,
germline SNPs were called and the transition to transversion and
dbSNP (Single Nucleotide Polymorphism Database) [20] 129
concordance ratios were calculated. For all three patients, the
transition/transversion ratios were in the range of 2.01 to 2.24,
and the dbSNP 129 concordance ratios were approximately 87%
Figure 1. Patient 1 Circos Plot. This plot summarizes all significant genomic events that were identified in patient 1 using WGS. Copy number
changes are shown in the inner circle plot with red marking amplifications and green marking deletions. SNVs are indicated with dark blue tick marks
and indels are indicated with light blue tick marks.
doi:10.1371/journal.pone.0043192.g001
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(Table 2). These analyses indicate that no biases were encountered
with respect to nucleotide substitutions, that SNPs identified in the
data strongly correlate with common genetic variations, and that
high quality variant calling was performed.
Variant Analysis. Aligned reads for both tumor and normal
libraries were evaluated to identify genomic events including non-
synonymous SNVs (nsSNVs), indels, and copy number variants
(CNVs). Summaries of identified variants in each patient are
shown in Figures 1, 2, and 3. Across all 3 patients, 142 coding
genomic events were identified. A total of 101 events were
identified in patient 1, 17 in patient 2, and 24 in patient 3. Of these
events, we identified 11 indels (Table 3), 69 nsSNVs (Table 3), and
62 focal/chromosomal CNVs (Table 4). These 62 CNVs
encompass approximately 4,576 genes across all 3 patients. 119
COSMIC (Catalogue of Somatic Mutations in Cancer) genes that
fall within these CNV regions are listed in Table 4. Using CREST,
we did not identify any significant somatic structural variants in
the 3 patients.
Whole transcriptome sequencing
Whole transcriptome sequencing was performed for patients 2
and 3 and normal human pancreatic RNA (Materials and
Figure 2. Patient 2 Circos Plot. This plot summarizes all significant genomic events that were identified in patient 2 using WGS. Copy number
changes are shown in the inner circle plot with red marking amplifications and green marking deletions. SNVs are indicated with dark blue tick marks
and indels are indicated with light blue tick marks.
doi:10.1371/journal.pone.0043192.g002
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Methods). RNAseq was not performed for patient 1 because tumor
RNA was not available. An average of 109 million mapped reads
was generated across the 3 analyzed samples. Tumor RNAseq
data was compared to normal human pancreatic RNAseq data to
identify expression changes in the tumor biopsies. Whole
transcriptome sequencing metrics are listed in Table 2.
RNA-seq Analysis. Overall, in patient 2, 1,841 genes showed
significant expression changes (q,0.05, corrected for multiple
testing), whereas in patient 3, 1,939 genes showed significant
changes. From these two analyses, 877 common genes/isoforms
were identified as showing significant expression changes. Genes
demonstrating both CNVs and significant expression changes (in
patients 2 and 3) are listed in Table S1. Putative fusion transcripts
identified in patients 2 and 3 are listed in Table S2.
Patient 1 analysis
Whole genome analysis. Well-established genes implicated
in PAC include BRCA2, TP53, CDKN2A (p16), MYC (v-myc
Figure 3. Patient 3 Circos Plot. This plot summarizes all significant genomic events that were identified in patient 3 using WGS. Copy number
changes are shown in the inner circle plot with red marking amplifications and green marking deletions. SNVs are indicated with dark blue tick marks
and indels are indicated with light blue tick marks.
doi:10.1371/journal.pone.0043192.g003
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Table 1. Patient clinical information.
Patient 1 Patient 2 Patient 3
Age at diagnosis (years) 55 76 57
Gender male female male
Ethnicity Caucasian Caucasian Caucasian
Diagnosis adenocarcinoma w/liver metastases adenocarcinoma w/no metastasis adenocarcinoma w/liver metastases
Tumor stage IV IIB IV
Tumor grade poorly differentiated moderately differentiated poorly differentiated
Tumor content 60% 50% 40–50%
Sequenced biopsy liver metastasis primary tumor liver metastasis
Clinical status Received treatmenta: deceased Did not receive treatment: no
recurrence after 24 months
Received treatmentb: deceased
aClinical benefit with FOLFOX (folinic acid, fluorouracil, oxaliplatin) systemic therapy for 24 weeks with 98% maximal serum CA19-9 reduction and partial metabolic
response by EORTC PET criteria.
bTransient clinical benefit with FOLFOX systemic therapy for 10 weeks with maximal serum CA19-9 reduction of 36% and RECIST (Response Evaluation Criteria in Solid
Tumors) reduction of 21% in sum of largest diameters.
doi:10.1371/journal.pone.0043192.t001
Table 2. WGS and RNAseq metrics.
WGS metrics Patient 1 Patient 2 Patient 3
Normal human
pancreas
Total amount of data generated (GB) 271.75 315.80 420.3 -
Q30 data generated (GB) 207.80 237.67 352.7 -
Average Total cluster densities (K/mm2) 381.36 681.31 569.21 -
Average PF cluster densities (K/mm2) 348.80 521.76 466.84 -
Average PF rate 76.43 76.61 83.4 -
Total number of reads 2256848363 2767484751 2878046795 -
Aligned Reads - Normal 1052366015 1441444310 1271057635 -
Aligned Reads - Tumor 1204482348 1326040441 1606989160 -
Aligned Bases - Normal 96863052455 1.4991E+11 1.3219E+11 -
Aligned Bases - Tumor 1.11483E+11 1.37908E+11 1.67127E+11 -
Average coverage depth - Normal 31.31 48.46 42.73 -
Average coverage depth - Tumor 36.04 44.58 54.03 -
Variant Analysis BWA BWA BWA -
Germline SNPs called 2013281 2129857 3610297 -
Transition/Transversion Ratio 2.24 2.17 2.01 -
dbSNP 129 rate 87.59 87.65 87.29 -
Non-synonymous germline variants 504 10151 12830 -
Somatic SNVs called (strict lists) 20323 714 25 -
False Positives (in dbSNP or 1000
Genomes) (strict lists)
0.107 0.41 0.36 -
Somatic indels called (CODING and UTR) 8 5 3 -
RNAseq
metrics
Total amount of data generated (GB) - 25.7 22.4 14.8
Q30 data generated (GB) - 21.1 18.4 12.2
Average Total cluster densities (K/mm2) - 810.0 694.0 1063.0
Average PF cluster densities (K/mm2) - 680.4 589.2 533.6
Average PF rate - 84.0 84.9 50.2
Total number of reads - 272694175 247382440 377376444
Total mapped reads - 124914613 104693716 98290756
doi:10.1371/journal.pone.0043192.t002
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Table 3. Indels and SNVs identified through WGS.
Patient Chr. Location Gene Name
Coding
event Alteration Sequence Change Effecta
1 13 31805365 BRCA2 Indel deletion AAAAG NMDb; frameshift
1 1 86818484 CLCA4 Indel deletion CCTACA no NMD
1 1 52078651 NRD1 Indel deletion TCT no NMD
1 9 124313206 OR1J2 Indel insertion T NMD unknown;
frameshift
1 8 8272117 SGK223 Indel insertion G NMD; frameshift
1 19 57578957 ZNF880 Indel deletion A NMD; frameshift
1 17 7518264 TP53 SNV R248W G/A damaging
1 12 25289551 KRAS SNV G12V C/A damaging
1 4 55642955 KDR SNV T1258M G/A damaging
1 3 131766828 COL6A6 SNV S321N G/A tolerated
1 4 185938530 ACSL1 SNV K143X T/A termination
1 11 129794256 ADAMTS8 SNV L288F G/A damaging
1 11 94172689 AMOTL1 SNV R229X C/T termination
1 4 114415228 ANK2 SNV G553R G/A damaging
1 10 28312788 ARMC4 SNV F270Y A/T tolerated
1 17 44591549 B4GALNT2 SNV T217M C/T damaging
1 7 33976531 BMPER SNV W123X G/A termination
1 4 24419470 CCDC149 SNV A336G G/C damaging
1 17 42569603 CDC27 SNV H615Q A/T damaging
1 16 79619379 CENPN SNV A305P G/C damaging
1 5 1387414 CLPTM1L SNV A294V G/A damaging
1 5 156718707 CYFIP2 SNV R232M G/T tolerated
1 1 55090513 DHCR24 SNV C511F C/A damaging
1 11 117156429 DSCAML1 SNV R118H C/T tolerated
1 19 48702891 ETHE1 SNV F239S A/G tolerated
1 4 126592198 FAT4 SNV L1824S T/C tolerated
1 2 169467273 G6PC2 SNV C97X C/A termination
1 4 144580767 GAB1 SNV P456Q C/A damaging
1 4 90388090 GPRIN3 SNV R732L C/A damaging
1 1 67628381 IL12RB2 SNV K676N G/T damaging
1 15 72213782 ISLR2 SNV R545H G/A damaging
1 X 48707520 KCND1 SNV R158H C/T damaging
1 6 24664901 KIAA0319 SNV D924N C/T tolerated
1 19 59437727 LILRA6 SNV E114D C/A tolerated
1 4 88985483 MEPE SNV I147F A/T damaging
1 7 141354973 MGAM SNV K109M A/T damaging
1 12 47726693 MLL2 SNV L1462F G/A no prediction
1 22 24494160 MYO18B SNV D95H G/C tolerated
1 11 112610991 NCAM1 SNV V8M G/A tolerated
1 4 96980836 PDHA2 SNV L171P T/C damaging
1 X 24816075 POLA1 SNV R1360H G/A tolerated
1 12 10926455 PRH1 SNV Q70H C/A damaging
1 9 134965563 RALGDS SNV V773I C/T damaging
1 7 5658630 RNF216 SNV H643P T/G tolerated
1 8 10505716 RP1L1 SNV P1101H G/T damaging
1 11 57138427 SERPING1 SNV P477T C/A tolerated
1 4 975236 SLC26A1 SNV Q86K G/T damaging
1 5 150648782 SLC36A3 SNV E89X C/A termination
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myelocytomatosis viral oncogene homolog), SMAD4, and KRAS.
Compared to the other sequenced patients, patient 1 harbored the
majority of genomic events in these genes including a deletion
within and CNV loss encompassing BRCA2, an SNV in TP53 (a
nonsynonymous mutation along with 17p hemizygous loss of the
wildtype allele), a homozygous deletion of the CDKN2A locus, and
an interstitial 8q CNV gain encompassing MYC. The deletion
identified in BRCA2 in patient 1 causes a frameshift and nonsense-
mediated decay of the transcript, whereas SNVs identified in
TP53, KRAS, and KDR are all associated with damaging effects on
the coding product. The alterations that affect BRCA2 suggest that
DNA repair mechanisms may be affected, thereby, providing an
explanation for the high number of somatic aberrations identified
in patient 1 compared to the other sequenced patient tumors.
BRCA2 germline mutations, in addition to being associated with
increased risk of breast and ovarian cancers [21,22,23] also occurs
in a small subset of both familial pancreatic cancer cases [24,25].
Although BRCA2 mutations have been identified in PAC, the
deletion we identify here in exon 10 of BRCA2 has not been
previously reported.
The R248 SNV identified in TP53 has been previously reported
in multiple cancers [26,27]. TP53 also fell within a region of CNV
loss in patient 1. The missense mutation is predicted to be
damaging and the SNV and CNV loss suggest that tumor
suppressor activity of TP53 may be compromised. Furthermore,
MDM2 (Mdm p53 binding protein homolog) demonstrated a
CNV loss. MDM2 is involved in regulation of TP53 activity such
that the cumulative effect of its CNV loss, along with the
alterations identified in TP53, suggest that regulation of TP53 and
TP53’s normal functions are impacted. A homozygous deletion of
Table 3. Cont.
Patient Chr. Location Gene Name
Coding
event Alteration Sequence Change Effecta
1 14 37748706 SSTR1 SNV R121C C/T tolerated
1 16 1068870 SSTR5 SNV M1V A/G damaging
1 9 129482338 STXBP1 SNV V515I G/A tolerated
1 3 33170461 SUSD5 SNV L223V G/C tolerated
1 16 19359304 TMC5 SNV G148V G/T damaging
1 3 113263420 TMPRSS7 SNV K343N G/T tolerated
1 1 173638901 TNR SNV A325E G/T tolerated
1 19 59634093 TTYH1 SNV P346L C/T tolerated
1 18 72721138 ZNF236 SNV V354L G/T tolerated
1 16 4755940 ZNF500 SNV E14G T/C tolerated
2 4 88756318 DSPP Indel deletion GACAGCAGC no NMD; frameshift
2 2 153184312 FMNL2 Indel insertion CCA no NMD
2 2 233420470 GIGYF2 Indel deletion ACA NMD; frameshift
2 8 89150850 MMP16 Indel insertion A NMD unknown;
frameshift
2 12 25289551 KRAS SNV G12V C/A damaging
2 19 2242562 LINGO3 SNV G72S C/T tolerated
2 17 1508349 PRPF8 SNV F1818C A/C damaging
2 21 43397525 U2AF1 SNV S34F G/A damaging
3 19 51042923 SYMPK Indel deletion GA no NMD
3 12 25289552 KRAS SNV G12R C/G damaging
3 17 47065916 CA10 SNV R295H C/T damaging
3 1 156418469 CD1D SNV A118T G/A tolerated
3 16 65505678 CDH16 SNV L241P A/G tolerated
3 10 135290149 FRG2B SNV T30S T/A tolerated
3 19 55006332 FUZ SNV L198F G/A possibly damaging
3 7 142361153 KEL SNV A313T C/T tolerated
3 14 23954072 KIAA1305 SNV A1093T G/A damaging
3 14 76650235 KIAA1737 SNV R341C C/T damaging
3 1 70277766 LRRC7 SNV A1191V C/T damaging
3 7 4251904 SDK1 SNV A2108T G/A tolerated
3 1 12300948 VPS13D SNV E2461K G/A tolerated
3 19 58772525 ZNF331 SNV E300A A/C damaging
aEffects were determined using SIFT/Polyphen-2.
bNMD=nonsense mediated decay.
doi:10.1371/journal.pone.0043192.t003
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CDKN2A was also identified to indicate that p16 tumor suppressor
functions are likely compromised. CNV loss of CDKN2A has been
previously reported in PAC [28]. Patient 1 also demonstrated a
previously reported mutation in KRAS for which glycine (G) is
converted to valine (V) at amino acid position 12 [29,30,31]. The
SNV in KDR, which codes for a tyrosine kinase VEGF (vascular
endothelial growth factor) receptor, has not been previously
reported in PAC. These genomic events identified in KDR and
KRAS may lead to dysregulation of signaling cascades upstream of
tumor cell proliferation to help promote tumor growth.
Copy number gains encompassing MYC indicate that this gene
is likely oncogenic in patient 1. Amplification of MYC has been
reported in PAC [32,33], and one study identified a positive
correlation between MYC amplification and tumor grade but not
survival [34]. Aside from commonly reported genes in PAC, APC
(adenomatous polyposis coli), MAP2K4 (mitogen-activated protein
kinase kinase 4), FHIT (fragile histidine triad), and AKT2 (v-akt
murine thymoma viral oncogene homolog 2) also fell in regions of
CNV loss. Mutations in APC have been reported in PAC
[35,36,37], and APC copy number loss has been reported in
colorectal cancer [38,39] and gastric cancer [40]. Due to APC’s
function as a tumor suppressor, decreased copy number of this
gene in patient 1 likely represents a key inactivating event in
patient 1’s cancer. Similar to APC, FHIT and MAP2K4, which
both may act as tumor suppressors [41,42,43], demonstrated copy
number losses and may also represent inactivating aberrations. A
copy number loss in FHIT has also been previously reported in
PAC [28], and mutations in MAP2K4 have been identified in
pancreatic and other cancers [41,42]. Lastly, AKT2, a putative
oncogene, has been reported to be amplified in pancreatic cancer
[44].
Somatic CNV losses identified using WGS also encompassed
RB1 (retinoblastoma 1), another tumor suppressor. Copy number
losses in TP53, AKT2, APC, MAP2K4, and RB1 represent key
events likely associated with tumor progression and growth in
patient 1. Additional relevant genes that fell in CNV regions
identified using WGS are listed in Table 4 and include PIK3R1
(phosphoinositide-3-kinase, regulatory subunit 1 (alpha)), MLLT3
Table 4. Copy number changes identified through WGS.
Patient Chromosome CNVa
Physical Position
(Mb) Patient Chromosome CNV1
Physical Position
(Mb)
1 1p Loss 0.8–29.0 1 13q Focal Loss 18.6–20.7
1 1q Focal Gain 143.7–144.0 1 13q Loss 25.2–87.2
1 20p Loss 0.2–18.8 1 13q Focal Loss 111.7–114.2
1 21p Focal Gain 9.9 1 14q Loss 41.4–73.3
1 21q Loss 13.9–46.9 1 15q Focal Gain 19.3
1 22q Focal Loss 15.4–16.7 1 16p Focal Loss 0.5–1.3
1 2p Loss 17.6–63.3 1 16q Focal Gain 69.7
1 2q Loss 189.0–242.5 1 17p Loss 0.06–21.2
1 3p Loss 38.5–77.2 1 18p Loss 3.2–10.7
1 3q Gain 162.1–175.5 1 18q Focal Loss 71.0–76.0
1 4p Loss 0.3–20.7 1 19p Loss 0.2–24.1
1 4q Loss 184.0–189.4 1 19q Loss 34.3–59.4
1 5q Loss 52.9–133.8 2 1p Loss 53.3–115.0
1 5q Focal Loss 69.3–70.4 2 1q Loss 177.8–198.4
1 5q Focal Loss 118.3–119.0 2 3q Focal Gain 106.7–107.0
1 6p Focal Loss 32.1–32.1 2 5p Focal Gain 1.3
1 6q Loss 57.1–134.6 2 5p Gain 31.5–50.8
1 6q Loss 154.4–170.8 2 8q Focal Gain 131.2–135.7
1 6q Focal Loss 157.6–158.0 2 15q Focal Gain 19.8–19.9
1 6q Focal Loss 167.9–168.0 2 17p Focal Loss 0.09
1 7p Loss 0.5–6.0 2 18p Gain 9.1–14.2
1 7q Focal Loss 74.1 3 1p Focal Loss 1.1–3.6
1 8p Focal Loss 21.9–30.1 3 1p/q Gain 120.0–143.7
1 8q Gain 100.8–146.3 3 3q Focal Loss 121.8–121.9
1 9p Loss 0.3–27.5 3 4p Focal Loss 1.7–3.4
1 9p Focal Loss 19.7–22.0 3 4q Focal Loss 69.1
1 10p Loss 0.2–22.4 3 5p Focal Gain 32.4
1 10q Loss 67.6–135.3 3 9q Focal Loss 136.3–138.4
1 11p Loss 0.2–36.3 3 12p Focal Gain 23.9–26.4
1 12q Loss 60.5–132.3 3 18q Focal Loss 74.8–75.3
aFocal gains/losses are defined as CNVs occurring across regions that are ,= 5 Mb.
doi:10.1371/journal.pone.0043192.t004
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(myeloid/lymphoid or mixed-lineage leukemia), FGFR2 (fibroblast
growth factor receptor 2), ALK (anaplastic lymphoma receptor
tyrosine kinase), EML4 (echinoderm microtubule associated
protein like 4), and HRAS (v-Ha-ras Harvey rat sarcoma viral
oncogene homolog), all of which demonstrated copy number losses
and all of which have not been reported in PAC. A total of 43
regions demonstrating CNV alterations, and which encompassed
4,426 genes, were identified in patient 1. Structural variant
analysis did not identify any aberrations in the tumor genome of
patient 1.
We further performed aCGH analysis on patient 1’s tumor and
validated all CNVs described here (Table S3). aCGH analysis also
identified biallelic deletion of NF2 (neurofibromin 2), a tumor
suppressor gene, which was initially not reported due to CNV
threshold cutoffs in the WGS analysis but which was subsequently
confirmed in the whole genome sequence data. This gene has not
been implicated in PAC but one study on pancreatic endocrine
tumors localized tumor suppressor loci to regions that include NF2
[45].
Summary. Many patients who are treated with gemcitabine
and 5-FU based treatments often fail and are thus interested in
and positioned to try additional agents that might offer benefit.
Knowledge of the specific mutations in a patient’s cancer may
indicate targetable drivers and an oncologist and physician may
decide to empirically treat the tumor based off the hypothesis that
targeting the mutant may offer benefit. Our WGS findings thus
provide insight into potential therapeutic options as well as
patients’ responses to treatments. For patient 1, based off the
deletion and copy number loss identified for BRCA2, potential
therapies include platinum compounds (cisplatin/carboplatin),
mitomycin C, or alkylators. Following the collection of the tumor
biopsy for sequencing, patient 1 was treated with a platinum
compound (oxaliplatin) as a part of FOLFOX (folinic acid,
fluorouracil, oxaliplatin) treatment. Patient 1 showed a complete
response, but subsequently developed resistance 6 months later.
Furthermore, the copy number loss identified for AKT2 may be
associated with patient 1’s initial response to gemcitabine prior to
biopsy as a recent study showed that AKT2 inhibition is associated
with increased gemcitabine sensitivity [46]. Other studies also
show that inhibition or silencing of AKT2 may block the growth of
tumor cells and tumor formation [47,48]. Patient 1’s partial
response was measured by EORTC PET (European Organisation
for Research and Treatment of Cancer positron emission
tomography) criteria along with normalization of CA19-9 (after
six months, the cancer progressed and developed elevation in
CA19-9). Overall, the BRCA2 deletion is likely the driving
mutation in this patient as the loss of DNA repair functions
permits the occurrence of mutations that, in this patient, affected
numerous genes including tumor suppressors. Given this finding,
the use of PARP (poly ADP ribose polymerase) inhibitors may
have represented a viable therapeutic option. Lowery et al.
reported treatments and responses of pancreatic cancer patients
with BRCA mutations and demonstrated the utility of using PARP
(poly (ADP-ribose) polymerase) inhibitors for these patients. This
finding and association provides evidence of the utility of
performing whole genome analyses of patients in order to identify
less common mutations that may be relevant for therapeutic
selection. Our identification of copy number losses in EML4 and
ALK, as well as the absence of an EML4-ALK fusion, also provides
evidence that crizotinib, an ALK inhibitor typically used to treat
non-small cell lung cancer, would not be an option for this patient.
Lastly, potential therapies that may be considered based on the
KDR mutation include sunitinib, a tyrosine kinase inhibitor, and
bevacizumab, which blocks the action of VEGFA (vascular
endothelial growth factor A).
Patient 2 analysis
Whole genome analysis. Patient 2 did not harbor any
events in BRCA2, TP53, CDKN2A, SMAD4, or MYC. Like patient
1, patient 2 also demonstrated a mutation in KRAS at the same
position (G12V). Overall, patient 2 demonstrated much fewer
genomic aberrations compared to patient 1 and did not
demonstrate aberrations affecting DNA repair genes. Structural
variant analysis using CREST did not identify any significant
somatic events in patient 2.
Aside from U2AF1 (U2 small nuclear RNA auxiliary factor 1),
SNVs and indels identified in patient 2 affect genes that have not
been previously reported in PAC or COSMIC. U2AF1 functions
as a part of the spliceosome and mutations in this gene have been
identified in myeloid hematopoietic cancers including chronic
myelomonocytic leukemia [49,50]. The SNV in U2AF1 identified
in patient 2 is predicted to be damaging such that proper splicing
of transcripts may be affected. A nine base pair deletion, causing a
frameshift, was identified in DSPP (dentin sialophosphoprotein),
which has been reported in oral squamous cell carcinoma
[51].This gene codes for tooth extracellular matrix proteins so its
potential role in PAC is unclear. We identified a frameshift
insertion in FMNL2 (formin-like 2), which normally functions to
regulate processes requiring actin, including cytokinesis, invasion,
and cell motility. Although FMNL2 mutations have not been
reported in PAC, it may have roles in colorectal carcinoma
[52,53,54] and hepatocellular carcinoma [55]. For GIGYF2
(GRB10 interacting GYF protein 2), we identified a frameshift
deletion. GIGYF2 was shown to interact with RQCD1 (RCD1
required for cell differentiation1 homolog) and may be involved in
regulating the activity of AKT in the EGFR pathway in breast
cancer [56,57]. Although GIGYF2 has not been described in PAC,
the deletion and resulting frameshift in patient 2 may affect normal
functions associated with AKT regulation. Interestingly, MMP16
(matrix metallopeptidase 16 (membrane-inserted)), which shows a
single base insertion in patient 2, was previously found to be the
target of a micro-RNA whose over-expression inhibited migration
and invasion of the MIA PaCa-2 pancreatic cancer cell line [58].
This finding suggests that MMP16 may be involved with
migration and invasion of pancreatic cancer cells. In a recent
exome sequencing study of intraductal papillary mucinous
neoplasms of the pancreas, PRPF8 (PRP8 pre-mRNA processing
factor 8 homolog) was recently found to garner a mutation
(A1842V) resulting from a SNV (C.T) [59]. This mutation differs
from the SNV we identified in patient 2, and has not been
reported in PAC or other cancers, but provides evidence of a
potential role of this gene, which functions in pre-mRNA splicing,
in PAC.
In patient 2, we identified 9 regions, covering 114 genes that
demonstrate copy number alterations (Table 4). These regions
encompass CBLB (Cbl proto-oncogene, E3 ubiquitin protein ligase
B), IL7R (interleukin 7 receptor), LIFR (leukemia inhibitory factor
receptor alpha), and NDRG1 (N-myc downstream regulated 1), all
of which showed copy number gains. CBLB has not been
implicated in PAC, but mutations in this gene have been identified
in leukemias [60,61]. IL7R also has not been previously reported
in PAC, but has been found to demonstrate activating mutations
in lymphoblastic leukemias [62,63,64]. LIFR has been reported in
other malignancies including colorectal and hepatocellular carci-
nomas [65,66], and is also suggested to have a role in tumor
growth in pancreatic cancer [67]. Lastly, NDRG1 has not been
reported in pancreatic cancer but is suggested to arrest metastasis
Sequencing of Pancreatic Adenocarcinoma Patients
PLOS ONE | www.plosone.org 11 October 2012 | Volume 7 | Issue 10 | e43192
Table 5. Selecteda differentially expressed genes identified using RNAseqb.
Patient Gene
ln (fold
change) q-value (corrected) Patient Gene ln (fold change) q-value (corrected)
2 AKT3 24.37 2.92E-03 3 ABL1 5.51 5.50E-03
2 ATM 23.84 2.25E-02 3 AKT2 4.42 4.52E-02
2 ATRX 23.19 4.89E-02 3 ATRX 25.32 3.12E-05
2 ATRX 25.68 5.53E-06 3 BCL3 4.43 4.40E-03
2 BCL3 4.42 4.77E-03 3 BCL3 3.93 1.40E-02
2 BCL3 4.25 1.05E-02 3 BIRC3 6.64 2.06E-07
2 BIRC3 5.86 1.67E-05 3 BRCA1 5.22 2.58E-04
2 BRCA2 3.48 2.31E-02 3 CDH1 23.38 1.93E-02
2 CBLB 4.54 1.74E-03 3 CDH11 5.94 1.10E-03
2 COL1A1 3.42 3.88E-02 3 CREBBP 3.94 4.65E-03
2 CREB1 3.75 1.79E-02 3 DNM2 23.27 4.73E-02
2 ERBB2 3.96 1.39E-02 3 EML4 23.26 1.87E-02
2 ERBB4 25.98 4.53E-08 3 ERCC4 24.05 2.27E-03
2 ERCC4 25.50 1.37E-05 3 FGFR1 22.98 4.97E-02
2 FGFR1 24.56 1.17E-02 3 FSTL3 4.23 5.35E-03
2 FGFR1 26.44 4.06E-02 3 GOLGA5 22.82 4.28E-02
2 FLT3 24.82 3.02E-03 3 HERPUD1 23.21 1.67E-02
2 FLT3 24.94 2.17E-03 3 IL7R 24.38 2.09E-03
2 FOXP1 23.23 3.85E-02 3 KRAS 4.35 1.61E-03
2 FUS 3.89 1.16E-02 3 MAML2 3.47 3.65E-02
2 GNAS 23.81 5.77E-03 3 MDM4 23.22 2.03E-02
2 GSK3B 3.33 1.60E-03 3 MLH1 4.12 6.01E-03
2 HERPUD1 24.86 1.40E-04 3 MLL3 2.99 4.69E-02
2 KTN1 23.84 5.91E-03 3 MLL3 23.13 1.86E-02
2 MAML2 3.45 4.62E-02 3 MLLT6 3.08 3.75E-02
2 MLL3 3.46 1.77E-02 3 NDRG1 4.05 3.35E-03
2 MLL3 23.47 6.01E-03 3 NFIIB 23.10 3.29E-02
2 NDRG1 5.71 2.73E-05 3 NOTCH2 4.12 7.57E-03
2 NFIIB 23.23 2.54E-02 3 PALB2 4.41 5.20E-03
2 NFIIB 23.43 1.17E-02 3 PICALM 3.28 3.40E-02
2 PIM1 4.90 1.42E-03 3 PIM1 3.84 2.57E-02
2 PPARG 3.82 3.95E-02 3 PPARG 4.44 2.54E-02
2 PRDM1 4.36 3.80E-03 3 REG4 6.92 2.04E-07
2 PRDM1 3.66 2.19E-02 3 REG4 6.49 5.05E-07
2 REG4 4.57 1.85E-03 3 REG4 4.77 3.84E-04
2 REG4 3.43 1.76E-02 3 RUNX1 3.61 8.25E-03
2 RUNX1 3.92 6.18E-03 3 TOP2A 8.99 2.97E-04
2 SET 4.04 6.85E-03 3 TOP2A 8.30 1.24E-03
2 SOX2 3.57 2.75E-02 3 TPM4 3.99 8.54E-03
2 TFPT 3.87 1.21E-02
2 TFRC 4.71 6.57E-04
2 TOP2A 9.15 2.05E-04
2 TP53 4.24 5.10E-03
2 TPM4 4.24 3.63E-03
2 ZNF384 25.56 1.57E-05
aSelected genes are genes that are reported in COSMIC.
bRNAseq was performed on patients 2 and 3.
doi:10.1371/journal.pone.0043192.t005
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in prostate and colon cancers [68,69]and it was also shown that
NDRG1 expression suppresses tumor cell growth [70].
Copy number validation was performed using flow sorted
aCGH which involves flow sorting nuclei from the tumor biopsy to
identify aneuploid populations. The sorted aneuploid population is
then separately analyzed using aCGH. Using this analysis, we
validated CNV gains identified using WGS in CBLB, IL7R, LIFR,
and NDRG1 (Table S3).
Whole transcriptome analysis. 1,841 genes demonstrating
significant expression changes (q,0.05, corrected for multiple
testing) in the tumor were identified. COSMIC genes demon-
strating significant expression changes are listed in Table 5. Genes
showing significantly altered expression in the tumor and that also
fall in regions of copy number change are listed in Table S1.
Putative fusion transcripts identified in patient 2, of which 2
contributing genes showed significantly altered expression, are
listed in Table S2. As structural variant analysis did not detect
significant somatic aberrations, the fusion transcripts detected in
patient 2 are not correlated with genomic data.
Transcriptomic analysis led to the identification of significantly
altered expression of genes that have been previously implicated in
cancer. Significantly up-regulated genes in the tumor include
GSK3b (glycogen synthase kinase 3 beta), BRCA2, TP53, TOP2A
(topoisomerase II alpha 170 kDa), BCL3 (B-cell CLL/lymphoma
3), and REG4 (regenerating islet-derived family, member 4).
Mutations in GSK3b have not been reported in PAC, but its
increased expression in patient 2 may have a role in contributing
to tumor malignancy and proliferation through SEMA3A [71].
TOP2A and REG4 have been previously found to be associated
with pancreatic cancer [70,71], whereas BCL3 has been found to
be associated with other cancers [72,73]. Additional up-regulated
genes that fall in the COSMIC database include MLL3 (myeloid/
lymphoid or mixed-lineage leukemia 3), BIRC3 (baculoviral IAP
repeat containing 3), ERBB2/HER2 (v-erb-b2 erythroblastic
leukemia viral oncogene homolog 2), PPARG (peroxisome
proliferator-activated receptor gamma), and CBLB, for which we
also identified a copy number change. Mutations in MLL3 have
been previously identified in pancreatic cancer [72,73], and MLL3
was also identified as a candidate pancreatic cancer gene using a
mutagenic screen in mice [74]. BIRC3, which acts to block
apoptosis, was also previously reported to show increased
expression in pancreatic cancer [75] and was found to be
amplified in 22 pancreatic cancer cell lines [76]. ERBB2/HER2,
an EGFR family tyrosine kinase that is involved in cell
proliferation, has been frequently reported as demonstrating
increased expression in pancreatic cancer [77,78]. PPARG over-
expression has also been previously identified in PAC and its over-
expression was also found to be correlated with shorter survival
[79]. Interestingly, inhibition of PPARG has been shown to block
liver metastasis in a xenograft mouse model and motility of
pancreatic cancer cells in vitro [80], and may thus represent a
therapeutic target.
Down-regulated genes include ERBB4 (v-erb-a erythroblastic
leukemia viral oncogene homolog 4), ERCC4 (excision repair
cross-complementing rodent repair deficiency, complementation
group 4), and FGFR1 (fibroblast growth factor receptor 1). ERCC4
has been reported to possibly be associated with risk of developing
PAC [74], whereas FGFR1 has been implicated in lung cancer
[75,76] and bladder carcinoma [77]. Decreased expression of
ERBB4 has been found in non-metastatic pancreatic cancer [81]
and was reported to potentially influence metastasis of pancreatic
cancer cells [82].
Of the fusion transcripts identified in patient 2, 2 genes that
were identified as part of fusions also demonstrated statistically
significant expression changes (q-value,0.05, corrected; Table
S2). These genes include LMO2 (LIM domain only 2 (rhombotin-
like 1)) and BACH1 (BTB and CNC homology 1, basic leucine
zipper transcription factor 1), which were both identified in 1
putative fusion each. LMO2 was identified as the 59 gene in an
interchromosomal fusion with ACVR2A (activin A receptor, type
IIA). Interestingly, LMO2 has been implicated in B-cell lymphoma
[83] and prostate cancer [84] and is proposed to be a prognostic
marker of longer survival in pancreatic cancer based on expression
and immunohistochemical analyses [85]. Furthermore, a muta-
genic screen aimed at identifying candidate pancreatic cancer
genes led to the identification of point mutations in ACVR2A, in
addition to other genes [74]. While only 2 non-junction-spanning
reads support this chimera, this transcript may have relevant
implications in patient 2’s disease. BACH1 was identified as the 39
gene in an intrachromosomal fusion with C21Orf109 (LINC00189;
long intergenic non-protein coding RNA 189). 18 reads spanned
the fusion junction to demonstrate increased confidence in this
fusion. BACH1 has been found to bind and inhibit TP53 such that
its increased expression [86] and potential transcript fusion in
patient 2 may influence tumor suppressor functions of TP53.
While the exact function of C21orf109 is unknown, long non-
coding RNAs are known for their roles in transcriptional
regulation. The putative chimera reported here may thus affect
normal functions of this transcript and of BACH1. 2 additional
predicted fusions were identified (FAM18B2-CDRT4 and
SLC35A3-HIAT1) with 17 and 15 reads spanning the junctions,
respectively, but none of these genes have been reported in PAC
or other cancers.
Summary. Following resection of the tumor, patient 2 was
treated with chemoradiation followed by gemcitabine and
erlotinib, and at 16 months post-resection, has not experienced a
recurrence. The absence of somatic events affecting DNA repair
genes and genes including BRCA2, TP53, CDKN2A, SMAD4, and
MYC, as well as increased expression of BRCA2 and TP53 in the
tumor, may all contribute to the status of this patient. If a
recurrence were to occur, the increased expression of TOP2A
indicates that topoisomerase inhibitors may be a possible
treatment option. While additional studies are needed, up-
regulated expression of BIRC3 may provide evidence that
sorafenib, a small molecule inhibitor of tyrosine and RAF kinases,
and TRAIL (tumor necrosis factor-related apoptosis inducing
ligand) may represent possible therapeutic options. Ricci et al.
found that sorafenib down-regulates BIRC3 and MCL1 (myeloid
cell leukemia sequence 1) expression and in doing so, causes
TRAIL-resistant colon cancer cells to become sensitive to TRAIL,
which promotes apoptosis [87] (we did not however identify
statistically significant expression changes for MCL1 and TRAIL).
Lastly, the identification of over-expression of ERBB2/HER2
provides evidence that trastuzumab, a monoclonal antibody that
interferes with signaling through ERBB2/HER2, and/or lapati-
nib, which blocks ERBB1/EGFR and ERBB2 to obstruct cell
growth and division, may be possible treatment options. The
combined use of cetuximab and trastuzumab was found to be
more beneficial than gemcitabine with regards to regression and
survival when treating human pancreatic cancer xenografts [88].
Another study showed that a combined treatment of trastuzumab
and matuzumab (anti-EGFR monoclonal antibody) on human
pancreatic cancer xenografts demonstrated therapeutic benefit
[89], whereas the use of multiple anti-ERBB2 antibodies targeting
different ERBB2 epitopes also showed therapeutic benefit in mice
[90].
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Patient 3 analysis
Whole genome analysis. Patient 3 did not harbor any
events in BRCA2, TP53, CDKN2A, SMAD4, or MYC. However,
patient 3 demonstrated a KRAS mutation for which glycine (G) is
converted to arginine (R) at amino acid position 12 and also
showed a somatic CNV gain of 1.38 (log2 scale) in KRAS. The
missense G12R mutation has been reported in pancreatic cancer
[91,92] and other cancers [30,93]. Outside of KRAS, we identified
13 additional SNVs and indels, of which 7 are predicted to be
damaging or potentially damaging (Table 3).
FUZ (fuzzy homolog (Drosophila)), KIAA1305 (NYNRIN; NYN
domain and retroviral integrase containing), and KIAA1737
(uncharacterized) have not been implicated in any cancers. CA10
has been reported in chondroblastoma [94] and was identified as a
putative methylation marker in bladder cancer [95], but has not
been reported in PAC. ZNF331 (zinc finger protein 331) may have
a role in follicular thyroid adenomas [96], and has also been
implicated as a potential tumor suppressor in gastric cancer [97].
Because the SNV identified in ZNF331 is predicted to be
damaging, its putative role as a tumor suppressor may represent
a key event in this patient. Lastly, mutations in LRRC7 (leucine
rich repeat containing 7) have been identified in multiple cancers,
including skin, ovarian, and breast cancer, but not in PAC.
Overall, CNV analysis of patient 3 led to the identification of 10
regions, covering 34 genes that demonstrated CNV alterations
(COSMIC genes falling within these regions are listed in Table 4).
Aside from a gain in KRAS, other key affected genes include
NOTCH2 (notch homolog 2), which also showed CNV gains,
PDE4DIP (phosphodiesterase 4D interacting protein; myomega-
lin), and FGFR3 (fibroblast growth factor receptor 3) and MLLT4/
AF6 (myeloid/lymphoid or mixed-lineage leukemia (trithorax
homolog, Drosophila); translocated to, 4), which both showed
CNV losses. Interestingly, one animal study showed that
KRAS(G12D)/NOTCH2 knockout mice survived longer and
demonstrated no progression of pancreatic intraepithelial neo-
plasms (PanINs) compared to KRAS(G12D) and KRAS (G12D)/
NOTCH1 knockout mice, thereby, showing that NOTCH2 may
have a significant role in tumor malignancy and development [98].
PDE4DIP and FGFR3 have not been reported in PAC but
PDE4DIP was identified as a tumor marker for esophageal
squamous cell carcinoma [99], and mutations in FGFR3 have
been found in pancreatic endocrine tumors [100] as well as
bladder cancer [101,102]. Lastly, MLLT4 has also not been
reported in PAC but down-regulated expression of this gene is
reported to be associated with increased likelihood of relapse in
14.5 to 15% of breast carcinoma cases as well as unfavorable
prognosis [103,104]. As previously mentioned, no significant
somatic structural variants were identified for patient 3’s tumor.
Whole transcriptome analysis. In patient 3, 1,939 genes
were found to demonstrate significant expression changes
(q,0.05, corrected for multiple testing) in the tumor. Selected
genes are listed in Table 5 and genes that demonstrated both copy
number changes and significant expression changes are listed in
Table S1. Fusion transcripts identified in patient 3 are listed in
Table S2. Like patient 2, somatic translocations were not identified
so the fusion transcripts detected in patient 3 do not directly
correlate with the tumor genome sequence.
Similar to patient 2, significant up-regulated expression was
identified for TOP2A, BCL3, BIRC3, MLL3, PPARG, and REG4,
and down-regulated expression was identified for ERBB4, ERCC4,
and FGFR1. Patient 3’s biopsy also demonstrated increased
expression of PTCH1 (patched 1), BRCA1 (breast cancer 1, early
onset), DNM2 (dynamin 2), MDM4 (p53 binding protein homolog
(mouse)), NOTCH2, and KRAS. Although mutations in PTCH1, a
tumor suppressor, have not been reported in PAC, its increased
expression may influence tumor proliferation through the Sonic
hedgehog pathway [105]. Up-regulated BRCA1 expression
suggests that patient 3’s tumor may boast increased genomic
stability; such an increase in expression has also been identified in
putative tumor-initiating cells isolated from multiple pancreatic
cancer cell lines compared to bulk cells [106]. Interestingly, up-
regulated expression of DNM2 has been reported in pancreatic
cancer and was shown to be associated with increased tumor cell
migration and invasion in human pancreatic cancer cells in vitro
[107], and may thus represent a new therapeutic target for PAC.
MDM4 normally acts to block TP53’s tumor suppressor functions
such that its increased expression in patient 3’s tumor may be a
key malignant event in this patient. Increased expression of MDM4
has been identified in a number of other cancers that have wild
type p53, including head and neck squamous carcinoma [108],
breast cancer, and lymphoblastic leukemia [109]. One study
described MDM4 as an oncogene upon identifying the develop-
ment of spontaneous tumors in conditional transgenic mice
overexpressing MDM4, along with an increase in tumorigenesis
in offspring when these mice were crossed with TP53+/2 mice
[110]. While no mutations were identified in TP53 for this patient,
up-regulated expression of MDM4 and the other genes described
here provide valuable information for the identification of new
therapeutic targets and also provide insight on the biological
processes that are occurring within the tumor.
In patient 3, we detected putative fusion transcripts supported
by the identification of reads spanning the transcript breakpoint
(Table S2). With the exception of CAV1 (caveolin-1), the genes
identified in these fusions have not been reported in PAC. Over
expression of CAV1, which also demonstrated increased expression
(q,0.05, corrected) in our study, has been found to be associated
with disease recurrence in pancreatic cancer patients [111]. Its
increased expression and potential role in an interchromosomal
fusion transcript in our results indicates that these events may
influence tumor progression in this patient. Additional fusions, that
did not harbor junction-spanning reads, but have been previously
reported in PAC, were also identified. BCL3, which we’ve
previously described in this patient, was detected as the 39 gene
in a fusion with PHLPPL (PH domain and leucine rich repeat
protein phosphatase 2). Another gene that was identified in our
transcriptomic analyses in this patient and that was found to be a
fusion gene is REG4, for which multiple fusions were predicted.
These fusions include REG4-SLC23A2 (solute carrier family 23
(nucleobase transporters), member 2) and REG4-LARP1 (La
ribonucleoprotein domain family, member 1). Although the 39
genes in these fusions have not been reported in PAC, an in vitro
study showed that LARP1 may have a key role in cell migration
[112]. Other genes of interest that were found in separate putative
fusions include MAP4K4 (mitogen-activated protein kinase kinase
kinase kinase 4), S100A4 (S100 calcium binding protein A4),
MMP7 (matrix metallopeptidase 7), and IER3/IEX1 (immediate
early response 3). MAP4K4 was detected as the 39 gene in a fusion
with APLP2 (amyloid beta (A4) precursor-like protein 2), which
codes for a protein that was found in pancreatic cancer cell line
supernatant [113]. While the effect of this putative fusion is
unclear, MAP4K4 over expression, which was also identified here,
was reported in stage II PAC patients and was found to be
correlated with negative prognosis in these patients [114]. S100A4
was found to be in predicted intrachromosomal fusion with LZIC
(leucine zipper and CTNNBIP1 domain containing). One study
showed a relationship between S100A4 inhibition and increased
gemcitabine sensitivity in PAC cell lines [115]. While implications
for the predicted S100A4-LZIC fusion are not known, the
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increased expression of S100A4 that we identified in our RNAseq
analyses indicates that this gene may be a relevant therapeutic
target.
We also identified MMP7, which demonstrated significant
increased expression in patient 3’s tumor, as the 39 gene in a
putative fusion with EPHX1 (epoxide hydrolase 1, microsomal),
which was shown to not play a role in pancreatic cancer [116].
Over expression of MMP7, which has roles in cell proliferation
and differentiation, has been reported to be correlated with poor
prognosis in PAC and tumor stage [117,118,119] and has also
been reported specifically in liver metastases of pancreatic cancer
[117]. Given these findings, the possible presence of the MMP7
fusion transcript may not significantly affect MMP7’s normal
functions given the diagnosis and outcome of patient 3. Another
predicted chimera was an IER3-SERPINA6 (serpin peptidase
inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6)
fusion—both genes in this fusion also showed statistically
significant over expression in the tumor. While SERPINA6 has
not been reported as having a role in PAC, studies have shown
that IER3 expression is linked to both poor prognosis [120] and
improved prognosis [121] in PAC patients. While additional
experiments are necessary for clarifying the discrepancy across
these findings, the presence of an IER3 fusion may have had
implications on this patient’s prognosis. Because the effect of the
fusions detected here are unclear, additional sequencing and
compilation of chimeric transcripts are needed so that we can
begin to unveil the role of these species on pancreatic tumorigen-
esis.
Summary. Prior to biopsy, patient 3 was first treated with
TH-302, an investigational drug that activates nitroazole under
hypoxic conditions plus gemcitabine as part of a phase I clinical
trial. He had transient clinical benefit at first but progressed and
was then treated with gemcitabine and nab-paclitaxel, but the
disease continued to progress. Our identification of a copy number
gain in and increased expression of NOTCH2 may provide some
explanation for the patient’s responses to his first two treatments.
Up-regulated expression of NOTCH2 was identified in gemcita-
bine-resistant pancreatic cancer cells to suggest its possible
involvement in chemotherapy resistance [122]. Increased expres-
sion of NOTCH2 in patient 3 may be associated with disease
progression following gemcitabine treatments. NOTCH2 inhibi-
tors are thus a possible therapeutic option for this patient. A trial is
currently recruiting stage IV pancreatic cancer patients, for whom
tumor resection is not an option, to evaluate the efficacy of a
combined therapy of MK0752, a NOTCH inhibitor, and
gemcitabine hydrochloride. While additional analyses are needed,
increased expression of S100A4 in patient 3 also suggests that this
may be key target as S100A4 inhibition may be associated with
increased sensitivity to gemcitabine. Another potential treatment is
topoisomerase inhibitors given up-regulated TOP2A expression in
the tumor. Similar to patient 2 and although additional studies are
required, sorafenib and TRAIL may represent future options for
patients whose tumors over express BIRC3. Lastly, increased
expression of MDM4 in patient 3’s tumor indicates that MDM4
inhibitors may also be a possible future option for patients. This
option is preceded by Wang et al., who identified a benzofuroxan
Figure 4. Pathway analysis of WGS and RNAseq results. Whole genome and RNAseq data were integrated and analyzed using GeneGo’s
Metaminer Pancreatic Cancer Disease module to identify pathways that may be affected by mutations and/or significant expression changes (q-
value,0.05, corrected). The top pathways (minimum mapping p-value across all WGS and RNAseq datasets ,0.05) are summarized based off of
GeneGo maps. Breakdown of affected pathways in each patient are shown in Table S4.
doi:10.1371/journal.pone.0043192.g004
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derivative that acts as an MDM4 inhibitor and showed that this
small molecule inhibitor acts to promote apoptosis in a breast
cancer cell line [123].
Pathway Analysis
While the goal of this study is to perform patient-specific
analyses, we also performed pathway analysis across all patients to
evaluate affected biological processes. This type of analysis is
preceded by Jones et al. who performed whole genome and
expression analyses on 24 pancreatic ductal adenocarcinoma cell
lines and xenografts [72]. In this study, mutations, copy number
changes, deletions, and expression changes were identified using
targeted sequencing of exons, microarrays, and mRNA sequencing
using SAGE (Serial Analysis of Gene Expression) tags. Using this
approach, the authors identified 12 core signaling pathways for
pancreatic cancer. For our analyses, results from WGS were
integrated with RNAseq data to identify pathways that may be
affected across all 3 patients. The 142 identified genomic events,
including all genes falling in regions demonstrating CNVs, were
evaluated alongside significant expression changes (q,0.05,
corrected) in patients 2 and 3.
Using GeneGo’s Metaminer Pancreatic Cancer Disease mod-
ule, we evaluated the extent to which 21 annotated pancreatic
cancer pathways are affected in the three patients (Table S4). The
top pathway maps (minimum mapping p-value,0.05) that
demonstrated the lowest probability of genes mapping to the
specified map by chance are summarized in Figure 4. Genes
demonstrating both mutations and expression changes in the top
maps are listed in Table S5. As expected, integrated analysis of
WGS and RNAseq data indicated that the most highly affected
pathway is KRAS signaling in pancreatic cancer. Affected genes
include those that solely demonstrate mutations or expression
changes, as well as those that demonstrate both mutations and
expression changes. Known cancer genes that fall in the KRAS
signaling pathway and that demonstrated alterations include
KRAS, TP53, MYC, PTEN (phosphatase and tensin homolog),
and AKT2.
Genomic events and expression changes were also analyzed
across the entire GeneGo pathway database in order to perform
an unbiased global analysis and to identify processes that may not
be captured in the Pancreatic Cancer Disease module. The top
map categories that were identified as demonstrating the largest
number of alterations include prostatic neoplasms, hepatocellular
carcinoma, and pancreatic neoplasms (Table S4 and Figure 4).
Additional map categories outline hallmark processes of cancer
and tumorigenic pathways. Identification of pathways that are
implicated in other cancers (prostate and liver) provides insight as
to possibly novel interactions that are not reported or less common
in pancreatic cancer. Consistent with pathway analysis against
MetaMiner’s Pancreatic Cancer Disease Module, the most highly
affected pathway was KRAS signaling in pancreatic cancer
(Figure 4), followed by ligand-independent activation of androgen
receptor. The latter map is annotated with cell progression, cell
proliferation, and survival pathways in prostate cancer, and may
provide clues into processes that may drive tumorigenesis in PAC.
As expected, processes in the top pathways (minimum mapping
p-value,0.05) identified through NGS analyses overlap with the
12 core signaling pathways previously reported by Jones et al., who
also used GeneGo for pathway analysis. Overlapping processes
and pathways include KRAS signaling, apoptosis, cell adhesion,
and invasion. While apoptosis, cell adhesion, and invasion
processes represent hallmark features of pancreatic cancer and
other human cancers, the identification of KRAS signaling across
multiple PAC samples, as well as the identification of previously
reported KRAS mutations in the 3 patients analyzed here,
emphasizes the tumorigenic role of KRAS signaling in pancreatic
cancer. The high incidence of KRAS mutations in PAC [31,124],
along with the finding that patients who have a KRAS mutation
have negative clinical outcomes when treated with a commonly
prescribed combination of erlotinib, an EGFR inhibitor, and
gemcitabine [125], further indicates that processes surrounding
KRAS represent relevant therapeutic targets.
Although patient 1’s tumor demonstrated the highest number of
mutations, RNAseq data from patients 2 and 3 showed widespread
pathway overlap with these genomic events. Patient 1 also
uniquely harbors mutations that affect DNA repair pathways with
respect to mismatch and nucleotide excision repair, DNA damage-
induced responses, and BRCA1 as a transcription regulator. The
larger number of identified genomic events in patient 1 may be
associated with alterations in genes involved in DNA repair
pathways and likely represents passenger mutations. Although
tumors from patients 2 and 3 demonstrated fewer mutations,
RNAseq data from these two patients suggest that common
pathways are affected across all 3 patients.
Pathway analysis of WGS and RNAseq data allows us to
understand which tumorigenic processes are present across the
three patients. However, it is also important to recognize several
caveats including: (1) mutations that are detected in larger genes
(such as MAP2K4, NCAM1, LAMA1, and LAMC1, which are all
over 100 kb) have a greater probability of representing a random
mutation; the presence of such random events may bias pathway
analysis; (2) alterations may influence additional key processes that
are not annotated in the map database; (3) the tumor contents are
50% and 40 to 50% for patients 2 and 3, respectively, so that
smaller, but potentially important, expression changes in tumor
cells may not be readily identifiable; and (4) patient 2 was
chemotherapeutically naı¨ve and had her primary tumor se-
quenced whereas patients 1 and 3 were treated prior to biopsy
collection and had their metastases sequenced. Despite these
differences, pathway analysis allows us to evaluate commonly
affected pathways across all 3 patients. KRAS is the only gene that
harbored mutations (SNVs and a CNV) across all three patients
and that also demonstrated a focal CNV gain and significant
increased expression in patient 3.
Conclusion
Due to the lack of effectiveness of current treatments for PAC
patients, we are tasked with improving our understanding of
genomic aberrations and processes that drive PAC tumorigenesis,
tumor progression, and malignancy in order to identify and
develop efficacious treatments. Our approach involves individually
characterizing patients to fully understand the range of molecular
events associated with this disease. In this study, we report our
findings of 3 individual genomic characterizations of tumors
collected from 3 separate patients. In 2 of the 3 patients, we
additionally performed RNAseq on the same whole genome
sequenced biopsies to identify significant expression changes and
fusion transcripts that may be associated with tumorigenesis and
that may be linked to the genomic events identified from WGS.
With this patient-specific characterization, we identified potential-
ly actionable therapeutic targets and contribute our findings to the
research and clinical communities. Using this approach, we also
detected aberrations that have not been previously reported in
PAC, but may represent viable targets in other patients who also
carry the same alteration. While further studies are needed to
determine which aberrations are passenger and driver mutations,
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these results contribute valuable information to our understanding
of the disease.
The utility of RNAseq data is clear when considering our
analyses of patients 2 and 3, compared to patient 1. While WGS
allowed us to identify non-synonymous mutations and copy
number changes in patient 1, expression data provides more
information on likely affected biological processes. As needle
biopsies are most commonly performed, analyses are typically
limited by the availability of tumor biopsy tissue. This limitation
thereby obstructs proteomic analyses. However, by layering in
RNAseq data, we acquire a more detailed picture of potentially
tumorigenic events in individual patients. By evaluating these
changes, our aim is to demonstrate the utility of using NGS to
understand what molecular events are occurring in the tumors of
separate patients and to move towards a more detailed under-
standing of the spectrum of aberrations that occur in this disease.
In doing so, this information may point to additional therapeutic
options that clinicians may consider during therapeutic selection.
Furthermore, identification of targets that fall outside of FDA-
approved pharmaceuticals or clinical trials serves to provide novel
and relevant areas of research for drug development. One caveat
here is that such analyses are dependent on the quality and tumor
content of the biopsies that are collected. The percentage of tumor
cells in the 3 analyzed patients’ biopsies ranged from 40% to 60%,
average mapped coverages ranged from 316 to 546using WGS,
and using RNAseq, over 100 million mapped reads were achieved
in each of patients 2 and 3. We show that an average tumor
content of approximately 50% is sufficient for NGS analysis of
tumor biopsies. Under circumstances whereby only biopsies with
lower tumor contents are available, NGS analyses may prove to be
difficult, particularly for the identification of heterozygous
mutations, and otherwise will require an increase in coverage
and an increase in the number of reads needed to identify
pertinent genomic events and changes in gene expression. A
second caveat in this study is that mutations that were not present
in the original tumor may arise while patients are undergoing
therapy and potentially hinder the efficacy of the treatment. While
our understanding of the details surrounding such events is limited,
additional sequencing of patients at different time points before,
during, and after treatments, will allow us to begin to understand
the contribution of these aberrations to the disease.
Given our findings, the advantages of whole genome and
transcriptome NGS in cancer patients are threefold—(1) foremost
is our ability to survey the entire genome and transcriptome in
order to detect abnormalities that may be missed using currently
available cancer testing panels, (2) the identification of expression
changes that may be associated with genomic events or that point
to putative drug targets, and (3) the annotation of PAC genomes
that provide insight into the molecular and cellular events involved
in tumorigenesis. The utility of NGS has also been demonstrated
in other sequencing studies that have used this technology to
evaluate genomic rearrangements in pancreatic cancer [126] as
well as differences in clonal populations between primary and
metastatic pancreatic tumors [127]. Such advantages and appli-
cations are intertwined with rapid improvements in NGS
technologies. The throughput for sequencing has nearly doubled
within one year and is forecasted to continue to grow over the next
few years. While turnaround time and the pipeline from sample
collection to sequencing results are still being optimized, we
demonstrate that NGS represents a compelling solution to
obtaining detailed molecular information on tumor biopsies in
order to provide guidance for therapeutic selection. Such an
approach is applicable to all cancers for which tumor biopsy
material can be acquired and is an obvious and powerful method
for advancing our understanding of pancreatic cancer. Because we
are still early in this process, the diversity of the findings in each of
the 3 patients in this study does not come as a surprise. As we
continue to sequence patients, we will acquire a better under-
standing of the compendium of events that have a role in the
disease, determine what aberrations represent driver or passenger
mutations, and strengthen our knowledge base for identifying and
developing improved therapeutics.
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